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Abstract
Background. The aim of the study was to describe and evaluate longitudinal trends in laboratory test utilization over a 7-year
period from 2002 to 2008.
Method. Retrospective study using test request data from the Clinical Chemistry and Pharmacology Laboratory at Akademiska
Sjukhuset, a large tertiary care university hospital in Sweden. Changes in test utilization, charges, and expenditures during the
study period were used as main outcome measures.
Results. Laboratory test utilization increased by over 70%, with a mean annual increase of 9.3% during the study period. After
adjustment for inﬂation, the laboratory expenditures increased by 20.2% during the study period but represented only
approximately 2.0% of the hospital’s total expenditure in 2008. The test menu comprised 663 tests in 2008, an increase by
146% from 2002. The mean inﬂation-adjusted unit price charged per test increased from e34.9 to e37.5 during the study
period. The top 10, 20, and 30 tests accounted for, on average, 46.9%, 66.9%, and 75.5% of the total test volume during the
study period, and 47.8%, 66.4%, and 75.7% of the total test volume in 2008. In 2008, 10 analyses, i.e. 1.5% of the number of
tests on the menu, accounted for almost half the number of generated test results.
Conclusions. The total number of generated test results increased by over 70% in less than a decade. Even so, the laboratory’s
share of the hospital’s total expenditure remained low and virtually unchanged. A very small number of tests accounted for a
disproportionately large share of the total number of generated test results.
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Introduction
Being the main source of objective data aiding clin-
icians in 60%–70% of all critical decisions such as
diagnosis, treatment, and follow-up (1), laboratory
tests are an essential part of an efﬁcient health care
system. As the resources of the health care sector are
scarce, demands are raised to lower the costs while
maintaining the quality of care. The laboratories are
often among the ﬁrst sections to be targeted for
budget reductions, as their costs are easily discernible.
However, the impact of laboratory tests on health care
as a whole is wide-spread, and the monetary value of
their effects is difﬁcult to measure. Furthermore, it
has been demonstrated that a reduction in test
utilization produces disproportionately small true
cost reductions (2), and it is by no means certain
that simply reducing the number of ordered tests will
lead to a decrease in the overall health care costs.
Akademiska Sjukhuset is with its 300-year history
the oldest university hospital in Sweden and also one
of Sweden’s largest tertiary care medical centers. In
2008 the hospital had approximately 1,100 beds, with
58,000 admissions per year and more than 750,000
out-patient visits annually. Akademiska Sjukhuset
serves a population of 327,000 people in the county
of Uppsala, as well as the population in the surround-
ing counties.
As accurate and timely information on laboratory
test utilization is vital for ﬁnancial management of
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longitudinal trends in test utilization from the per-
spective of the Clinical Chemistry and Pharmacology
Laboratory at Akademiska Sjukhuset in Uppsala,
Sweden.
Materials and methods
Test utilization data from 1 January 2002 through
31 December 2008 were retrospectively extracted
from the Laboratory Information System. Informa-
tion on expenses, charges, admissions, and out-
patient visits was collected for the years 2002 and
2008 individually. In all presentations of costs, e1i s
equal to SEK10. Charges and expenditures were
analyzed after adjusting for inﬂation according to
the consumer price index (CPI), and the 2008 value
is presented. The CPI, set at 100 for 1980, was
272.85 in 2002 and 300.50 in 2008.
Tests were counted as follows: All incoming test
orders that generated a result, including non-
chargeable results such as calculations or missing or
ruined samples, were counted. Before they were
counted, all test orders were broken down into indi-
vidual analyses, so that the test volume presented here
contained no proﬁles, bundled tests, or test panels.
Results
The variables considered in this study and their
inﬂation-adjusted values for 2002 and 2008, respec-
tively, are presented in Table I. A total of
33,846,377 test results were generated in the Clinical
Chemistry and Pharmacology Laboratory during the
7-year study period. From 2002 to 2008 the number
of generated test results grew by 70.3%, with an
average increase of 9.30% or 440,352 test results
per year (Figure 1). On average 4,835,197 tests results
were generated annually during the study period.
A total of 1,005 send-out tests were ordered during
2002. The corresponding ﬁgure was 3,160 in 2008.
The mean price charged per test according to the
price-list (not volume-adjusted) increased by 7.4%, or
2.6 inﬂation-adjusted euros, from e34.9 to e37.5 per
test, during the study period. The total testing
expense (total expense/total number of generated
test results) was e2.8 in 2002 and e2.0 in 2008.
The 10, 20, and 30 most commonly ordered tests
accounted for, on average, 46.9%, 66.9%, and 75.5%
of the total number of generated test results during
the study period, and 47.8%, 66.4%, and 75.7% of
the total number of generated test results in
2008 (Table II).
The number of hospital admissions increased by
8.4% from 53,504 to 58,001 between 2002 and 2008.
In 2002, there were 291,000 out-patient visits with a
physician. During the study period this number grew
by 14.2% to 332,243. The number of additional out-
patient visits increased by 27.4% from 329,000 in
2002 to 419,213 in 2008. Between 2002 and
2008, the number of hospital beds decreased from
1,200 to 1,100, and the total hospital costs increased
by 22.6%. The total expenses of the Clinical Chem-
istry and Pharmacology Laboratory amounted to
e10.4 million in 2002 and e12.5 million in 2008,
representing an increase of 20.2%. The percentage of
the hospital’s expenditures that was constituted by the
costs of the Clinical Chemistry and Pharmacology
Laboratory decreased slightly by 0.1% to 2.0% during
the study period.
Discussion
The cost of health care in Sweden, as well as in many
other countries, increases every year (3–5) and more
rapidly so than the Gross Domestic Product (GDP)
(6). In 2002, the net costs of health care in
Sweden amounted to e15,459 million (2008 euros)
(7). By 2008, the total expenditure had reached
e20,640 million (7), an increase of 34% in less
than a decade. The GDP, on the other hand, had
during the same period only increased by approxi-
mately 17% (8). The total costs of health care in
Sweden, expressed as a percentage of GDP, were
in 2005 9.2% (9), i.e. slightly above the 8.9% average
of the OECD countries (10), but substantially lower
Table I. Investigated variables and their inﬂation-adjusted values
presented in 2008 euros.
2002 2008
Generated test results
a 3,760,508 6,402,617
Analyses offered 309 663
Send-out tests ordered 1,005 3,160
Mean price charged per test
b e34.9 e37.5
Total laboratory expenditures e10.4 million e12.5 million
Total testing expense
c e2.8 e2.0
Admissions 53,504 58,001
Hospital beds 1,200 1,100
Out-patient visits with a physician 291,000 332,243
Additional outpatient visits 329,000 419,213
Total hospital expenditures e513 million e629 million
aIncluding non-chargeable test results such as calculations and
missing or ruined.
bAccording to price-list, not volume-adjusted.
cTotal expense/total number of generated test results.
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GDP spent on health care in the US (10). The annual
total cost of laboratory testing in Sweden is approx-
imated at e0.8 billion (in 2008 euros), about half of
which is represented by the costs of clinical chemistry
tests (11). Of the total health care costs, laboratory
expenditures only account for approximately 4% in
Sweden (12). The corresponding ﬁgures are 20% in
the United States, 4% in the United Kingdom, 5.2%
in Australia, and 7%–10% in Canada (13). Though
laboratory tests only account for a very small part of
the total health care costs, the laboratories are
often among the ﬁrst to be targeted for budget reduc-
tions. However, the impact of laboratory tests on
health care as a whole is wide-spread, and the mon-
etary value of their effects is difﬁcult to measure.
Thus, the relation between test utilization, costs,
and quality of care is as complex as it is central to
health care management.
Very little has so far been published about changes
in test utilization over time. Accurate and timely
information on trends in test utilization is essential
to ﬁnancial management of clinical laboratories. The
aim of this study was therefore to elucidate the
changes over time in clinical chemistry and pharma-
cology test utilization, data that are not readily avail-
able. Studies such as this provide base-line data, a
necessity when planning for future adaptation and
improvements of test utilization and laboratory struc-
ture. To our knowledge, this is the ﬁrst Swedish study
of clinical chemistry and pharmacology test utiliza-
tion, charges, and expenses. This 7-year analysis was
designed to describe and evaluate trends in test uti-
lization, expenditures, and charges at a clinical chem-
istry laboratory at a large tertiary care university
medical center. The study provides insight into the
utilization and economics of laboratory testing during
the past 7 years, a period that was characterized by
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Figure 1. The total number of performed tests per year during the study period.
Table II. The percentage of the total number of tests represented by the 10, 20, and 30 most commonly ordered tests.
Year
Total number of
ordered tests
10 most commonly
ordered tests
20 most commonly
ordered tests
30 most commonly
ordered tests
2002 3,760,508 40.4% 59.5% 67.6%
2003 3,983,149 47.7% 69.7% 78.7%
2004 4,218,082 47.6% 69.1% 77.6%
2005 4,614,524 48.8% 69.3% 77.1%
2006 5,100,550 48.0% 67.4% 75.8%
2007 5,766,947 47.9% 66.7% 76.2%
2008 6,402,617 47.8% 66.4% 75.7%
Mean 4,835,197 46.9% 66.9% 75.5%
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about medical costs.
The principal ﬁndings of this study were substantial
increases in the number of generated test results and
in the number of tests offered, despite a virtually
unchanged share of the hospitals total expenses repre-
sented by the costs of laboratory testing. From 2002 to
2008 the work-load, as deﬁned by the number of
generated test results, increased by over 70%, with
a mean annual increase of 9.30%. This is higher than
the average laboratory test growth rate of 7.2% seen in
the Netherlands during the 1980s (14) but lower than
the average increase rate of 12.1% in the US in
1993 (15). Other similar studies have presented lab-
oratory test growth rates of 2.3%–13.8% at different
times during the period 1970–2005 (15–18), whereas
yet others have demonstrated virtually unchanged
(19) or declining utilization rates (20), the latter
most likely due to interventions aimed at reducing
test ordering. The percentage of the total number of
generated test results that was represented by send-
out tests increased slightly from 0.03% to 0.05% and
thus only accounted for a very small portion of the
total number of generated test results throughout the
study period.
As the mean price charged per test is skewed
upwards by a relatively small number of high-
cost analyses, it is not necessarily representative of
the general level of unit prices charged, but it is
nevertheless suitable for a comparison of trends.
The mean price charged per test had increased slightly
during the study period but at a rate lower than would
be expected considering the inﬂation rate as deﬁned
by the CPI. However, the data available in this study
do not allow analysis of the underlying cause of this.
As opposed to the mean price charged per test, the
total testing expense takes into account the prices
charged per test as well as the test utilization volumes.
This variable had, unlike the mean price charged per
test, decreased from e2.8 to e2.0 during the study
period, most likely due to a combination of increased
automation and efﬁciency.
The number of different analyses offered by the
Clinical Chemistry and Pharmacology Laboratory
was 663 in 2008, and had thus more than doubled
during the study period. Despite this, the share of the
total number of generated test results that was repre-
sented by the 10 most commonly ordered analyses
was very stable at approximately 50% throughout the
study period, indicating that most of the new tests that
were added to the test menu were low-frequency tests.
The 10, 20, and 30 most commonly ordered tests
accounted for, on average, 46.9%, 66.9%, and 75.5%
of the total test volume during the study period, and
47.8%, 66.4%, and 75.7% of the total test volume in
2008. In a study by Nexø, the top-20 tests represented
more than 80% of all test requests (19), whereas, in a
South African study, the 10 and 30 most commonly
ordered tests represented 36.3% and 67.8%, respec-
tively, of all ordered tests (17), results similar to those
presented in this study. Among the 10 most com-
monly ordered tests in this study, the intergroup order
of tests varied minimally during the study period and
mainly consisted of the components of the full blood
count with the addition of potassium, and occasion-
ally C-reactive protein (CRP). Among the 11–20 most
commonly ordered tests, the extent of intergroup
variation was slightly greater than in the top-10 group
and increasingly so further to the bottom of the group.
The group containing the top 21–30 tests, however,
was much less homogeneous than the two previous
groups. The continuity of different analyses was still
fairly high among the top 21–30 tests, but no test was
consequently represented in this group throughout
the study period. The data on the top-30 tests could
be useful as an indication of where small changes in
test utilization may bring about considerable savings,
as small technologies are likely to account for far more
of the over-utilization than big expensive technologies
(21), and low-cost high-frequency tests have been
demonstrated to account for the major proportion
of laboratory costs (22).
The number of admissions and out-patient visits
had increased by 20.2% during the study period.
Assuming the test-ordering pattern to be the same
for the admissions and out-patient visits in 2002 and
2008, the increase in the number of admissions and
out-patient visits would merely explain about one-
third of the increase in test volume. The major part of
the increase in work-load could thus most likely be
ascribed to intrinsic growth.
There are a few potential limitations of this study.
Firstly, the test utilization pattern at Akademiska
Sjukhuset may not be representative of that in Sweden
as a whole. Despite this limitation, the results warrant
evaluation and are indicative of trends in clinical
chemistry and pharmacology test utilization in
Sweden. Secondly, the way the tests are counted
will admittedly inﬂate test count, but this should
not inﬂuence the evaluation of trends in utilization,
with which this study is concerned. Thus, as ﬁltering
of test-ordering data would risk biasing the results, we
chose to present the raw, gross-type test-ordering
data. Furthermore, presentation of test volumes on
the basis of individual tests as opposed to test volumes
containing panels as bundled tests should facilitate
comparisons between laboratories and countries as
test panels include different tests in different settings.
Thirdly, as the total number of generated test
results included some non-chargeable results such
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slightly under-estimated. However, there is no reason
to believe that the number of non-chargeable results
varied signiﬁcantly during the study period, and this
would thus not affect the evaluation of trends. Lastly,
it should be noted, for this type of study in general,
that raw numbers of ordered tests do not reﬂect the
quality of the care provided and that they say nothing
of whether the tests were appropriately used.
The main strength of this study is that the data on
the utilization of a substantial number of clinical
chemistry and pharmacology tests, representing a
large patient population, were evaluated over an
extended period of time. The study deﬁnes trends
and may thus have potential predictive values.
Conclusion
In conclusion, the total number of generated test
results increased by over 70% in less than a decade,
whereas a very small number of tests accounted for a
disproportionately large share of the total number of
performed tests. Despite the substantial increase in
the number of generated test results, the laboratory’s
share of the hospital’s total expenditure remained low
and virtually unchanged at approximately 2% during
the study period.
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